Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of SARS-CoV-2 RBD Mutations on the Production of a Recombinant RBD Fusion Protein in Mammalian Cells.

Biomolecules - 24 Aug 2022

Gerez Guillaume, Martinez Jerome, Steinbrugger Christophe, Bouanich Sandra, Dimino Johanna, Piegay Corine, Combe Maxime, Berthier Franck, Daniel Soizic

Abstract excerpt

SARS-CoV-2 receptor-binding domain (RBD) is a major target for the development of diagnostics, vaccines and therapeutics directed against COVID-19. Important efforts have been dedicated to the rapid and efficient production of recombinant RBD proteins for clinical and diagnostic applications. One of the main challenges is the ongoing emergence of SARS-CoV-2 variants that carry mutations within the RBD, resulting...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to COVID-19
Share to Disulfides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HEK293 Cells

Share to Protein Disulfide-Isomerases

Share to Recombinant Fusion Proteins

Share to SARS-CoV-2

Share to Spike Glycoprotein, Coronavirus

Share to Viral Vaccines

Source

Open in PubMed Open full text

Identifiers

PMID: 36139010
DOI: 10.3390/biom12091170
PMCID: PMC9496381

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of SARS-CoV-2 RBD Mutations on the Production of a Recombinant RBD Fusion Protein in Mammalian Cells.PMID 36139010Read ↗

Designed SARS‐CoV‐2 receptor binding domain variants form stable monomersSemantic proximity Read ↗

Yeast-expressed Recombinant SARS-CoV-2 Receptor Binding Domain, RBD203-N1 as a COVID-19 Protein Vaccine CandidateSemantic proximity Read ↗

Genetic Modification to Design a Stable Yeast-expressed Recombinant SARS-CoV-2 Receptor Binding Domain as a COVID-19 Vaccine CandidateSemantic proximity Read ↗

Enhancing the Immunogenicity of RBD Protein Variants through Amino Acid E484 Mutation in SARS-CoV-2.Semantic proximity Read ↗

Scale-up Production and Immunological Assessment of Recombinant SARS- CoV-2 Spike RBD in Pichia pastorisSemantic proximity Read ↗

SARS-CoV-2 RBD219-N1C1: A Yeast-Expressed SARS-CoV-2 Recombinant Receptor-Binding Domain Candidate Vaccine Stimulates Virus Neutralizing Antibodies and T-cell Immunity in MiceSemantic proximity Read ↗

Challenges in Expression and Purification of Functional Fab Fragments in E. coli: Current Strategies and PerspectivesSemantic proximity Read ↗

Yeast-produced RBD-based recombinant protein vaccines elicit broadly neutralizing antibodies and durable protective immunity against SARS-CoV-2 infectionSemantic proximity Read ↗

Mutation of the proteolytic cleavage site enhances stability and yield of recombinant hepatitis C virus core protein in bacterial cells.Semantic proximity Read ↗

Process Development and Scale-up Optimization of the SARS-CoV-2 Receptor Binding Domain-Based Vaccine Candidate, RBD219-N1C1Semantic proximity Read ↗

High-level expression of the monomeric SARS-CoV-2 S protein RBD 320-537 in stably transfected CHO cells by the <i>EEF1A1</i> -based plasmid vectorSemantic proximity Read ↗

Structural and functional comparison of SARS-CoV-2-spike receptor binding domain produced in Pichia pastoris and mammalian cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.